Qube Research & Technologies LTD Uni Qure N.V. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$5.63 - $8.27 $282,051 - $414,310	-50,098 Reduced 42.13%	68,813 $465,000
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $797,892 - $1.41 Million	118,911 New	118,911 $797,000
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $530,294 - $654,219	-28,358 Reduced 58.26%	20,320 $409,000
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $882,045 - $1.33 Million	48,678 New	48,678 $1.1 Million
Q1 2022 May 09, 2022	SELL	$14.54 - $21.5 $158,980 - $235,081	-10,934 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$20.24 - $36.01 $221,304 - $393,733	10,934 New	10,934 $227,000
Q3 2020 Nov 12, 2020	SELL	$35.98 - $47.66 $609,645 - $807,551	-16,944 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $763,496 - $1.15 Million	16,944 New	16,944 $763,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.